The N-hetero Ring Is Part Of A Bicyclic Ring System Patents (Class 536/26.7)
-
Patent number: 8716262Abstract: A nucleoside compound having activity against hepatitis C virus is disclosed.Type: GrantFiled: December 23, 2009Date of Patent: May 6, 2014Assignee: Gilead Pharmasset LLCInventors: Michael Joseph Sofia, Jinfa Du, Peiyuan Wang, Dhanapalan Nagarathnam
-
Publication number: 20140123342Abstract: The role of extracellular nucleotides and apyrase enzymes in the guard cells that border stomata in regulating stomatal aperture and the plant's resistance to drought and pathogens is disclosed herein. Expression of apyrases APY1 and APY2, in guard cell protoplasts is strongly correlated with cell growth, cell secretory activity and with conditions that favor stomatal opening. Both short-term inhibition of ectoapyrase activity and long-term suppression of APY1 and APY2 transcript levels significantly disrupt normal stomatal behavior in light. Furthermore, two punnoceptor inhibitors in mammals, pyridoxalphosphate-6-azo-phenyl-2?,4?-disulphonic acid (PPADS) and Reactive Blue 2, block ATPS- and ADP?S-induced opening and closing, and also partially block the ability of abscisic acid (ABA) to induce stomatal closure, and light-induced stomatal opening.Type: ApplicationFiled: June 1, 2012Publication date: May 1, 2014Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Stanley J. Roux, Iris Steinebrunner, Gregory B. Clark
-
Publication number: 20140112887Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2?,4?-bridged nucleosides which display remarkable efficacy and bioavailability for the treatment of, for example, HCV infection in a human. In certain embodiments, the 2?,4?-bridged nucleosides are of Formula 3001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, where PD, B, W, X, RA, RB, RC and RD are as described herein.Type: ApplicationFiled: October 21, 2013Publication date: April 24, 2014Inventors: Benjamin Alexander MAYES, Adel M. MOUSSA, Alistair James STEWART
-
Publication number: 20140106451Abstract: Provided herein are novel bicyclic nucleosides, oligomeric compounds that include such bicyclic nucleosides and methods of using the oligomeric compounds. More particularly, the novel bicyclic nucleosides comprise a furanose ring system having a bridge comprising a 4?-methylene group attached to a 2?-sulfoxide or sulfone group and optionally including one or more substituent groups attached to the 4?-methylene and or the 5?-position. In certain embodiments, the oligomeric compounds provided herein are expected to hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.Type: ApplicationFiled: October 9, 2013Publication date: April 17, 2014Inventors: Thazha P. Prakash, Eric E. Swayze
-
Patent number: 8697861Abstract: The invention is related to phosphorus substituted anti-viral inhibitory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.Type: GrantFiled: September 25, 2012Date of Patent: April 15, 2014Assignee: Gilead Sciences, Inc.Inventors: Constantine G. Boojamra, Kuei-Ying Lin, Richard L. Mackman, David Y. Markevitch, Oleg V. Petrakovsky, Adrian S. Ray, Lijun Zhang
-
Publication number: 20140100186Abstract: A method of modifying a nucleotide or a nucleotide analogue to increase its overall effectiveness in treating an antiviral disease is provided. In some cases, a compound comprising a base, sugar, phosphonate moiety, and amino acid residue is provided, where the base-sugar may be a nucleoside, and the amino acid residue may be a tyrosine residue. In certain cases, the tyrosine residue contains a long chain alkyl group on the carboxamide group of the residue. Methods of inhibiting viral replication and methods of treating a viral infection are also provided.Type: ApplicationFiled: May 7, 2012Publication date: April 10, 2014Inventors: Charles E. McKenna, Boris A. Kashemirov, Ivan S. Krylov, Valeria M. Zakharova
-
Publication number: 20140099283Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2?-chloro nucleosides according to Formula 2001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein B, Z and PD are as described herein.Type: ApplicationFiled: October 7, 2013Publication date: April 10, 2014Inventors: Gilles GOSSELIN, Christophe Claude PARSY, Francois-Rene ALEXANDRE, Houcine RAHALI, Jean-Francois GRIFFON, Julien MILHAU, Dominique SURLERAUX, Cyril B. DOUSSON, Claire PIERRA, Adel M. MOUSSA, Benjamin Alexander MAYES
-
Patent number: 8691971Abstract: Disclosed herein are compositions and methods for generating ribo-nucleic neutral (RNN) or deoxyribo-nucleic-neutral (DNN) polynucleotides with reduced anionic charge, for improved intracellular delivery. Also disclosed herein are methods of using RNN and DNN compositions.Type: GrantFiled: September 23, 2009Date of Patent: April 8, 2014Inventor: Scott G. Petersen
-
Publication number: 20140086873Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, provided herein are compounds according to Formula 1001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein Base, Y, Z, A, RC and RD are as described herein.Type: ApplicationFiled: September 26, 2013Publication date: March 27, 2014Inventors: Benjamin Alexander Mayes, Adel M. Moussa
-
Patent number: 8680071Abstract: Provided herein are compounds, compositions and methods for the treatment of liver disorders, including HCV infections. In one embodiment, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.Type: GrantFiled: March 31, 2011Date of Patent: March 25, 2014Assignees: Idenix Pharmaceuticals, Inc., Centre National de la Recherche ScientifiqueInventors: Dominique Surleraux, Gilles Gosselin
-
Publication number: 20140066395Abstract: The present invention is directed to compounds, compositions and methods for treating or preventing cancer and viral infections, in particular, HIV, HCV, Norovirus, Saporovirus, HSV-1, HSV-2, Dengue virus, Yellow fever, and HBV in human patients or other animal hosts. The compounds are certain 6-substituted purine monophosphates, and pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof. In particular, the compounds show potent antiviral activity against HIV-1, HIV-2, HCV, Norovirus, Saporovirus, HSV-1, HSV-2, Dengue virus, Yellow fever, and HBV.Type: ApplicationFiled: September 20, 2013Publication date: March 6, 2014Applicants: Emory University, RFS Pharma, LLCInventors: Jong Hyun Cho, Steven J. Coats, Raymond F. Schinazi, Hongwang Zhang, Longhu Zhou
-
Patent number: 8658617Abstract: The invention is related to salts of anti-viral compounds, compositions containing such salts, and therapeutic methods that include the administration of such salts, as well as to processes and intermediates useful for preparing such salts.Type: GrantFiled: July 7, 2009Date of Patent: February 25, 2014Assignee: Gilead Sciences, Inc.Inventors: Benjamin R. Graetz, Richard Polniaszek
-
Publication number: 20140051605Abstract: The present disclosure relates to photoactivable protecting groups containing a diarylsulfide chromophore, a method for the synthesis thereof and their use as photoactivable protecting groups using maskless photolithography based array synthesis.Type: ApplicationFiled: October 23, 2013Publication date: February 20, 2014Applicant: NimbleGen Systems GmbHInventor: Klaus-Peter Stengele
-
Publication number: 20140046021Abstract: The molecular structures of metal-salen complexes which exerts pharmacological effects are clarified and the metal-salen complexes having such molecular structures and their derivatives are provided. A metal-salen complex compound is characterized in that a metal atom part in each of multiple molecules of the metal-salen complex or its derivative is multimerized via water.Type: ApplicationFiled: January 19, 2012Publication date: February 13, 2014Applicants: IHI CORPORATIONInventors: Yoshihiro Ishikawa, Haruki Eguchi
-
Publication number: 20140038916Abstract: This application discloses novel phosphoramidate and phosphonoamidate prodrugs of nucleosides, nucleotides, C-nucleosides, C-nucleotides, phosphonates, and other alcohol-containing drugs; use of these prodrugs for treatment of infectious diseases and cancers, in particular, liver infections and cancers; and methods of preparing these novel phosphoramidate and phosphonoamidate prodrugs.Type: ApplicationFiled: December 30, 2011Publication date: February 6, 2014Applicant: Nanjing Molecular Research, Inc.Inventors: Zheng Wang, Suping Zhou
-
Publication number: 20140038912Abstract: Provided are adenosine analog compounds of the general formula that act as P2Y receptors, e.g., the P2Y2 receptor, including pharmaceutical compositions; and uses thereof to treat or prevent diseases associated with that receptor, e.g., disorders relating to mucus secretion, such as cystic fibrosis, chronic obstructive pulmonary disorder (COPD), asthma, constipation, chronic idiopathic constipation, dry mouth (xerostomia), gum disease, and gastrointestinal problems caused by radiation and chemotherapy for cancer.Type: ApplicationFiled: October 11, 2013Publication date: February 6, 2014Applicant: MICRODOSE THERAPEUTX, INC.Inventors: Efrat Ben-Zeev, Vincent Jacques, Yael Marantz, A. Sekar Reddy, Zhaoda Zhang, Oren Becker, Dilara McCauley, Pini Orbach, Sharon Shacham, Ashis K. Saha, Michael Xie
-
Publication number: 20130338095Abstract: Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory receptor ligand. Also provided herein are chemosensory receptor ligand compositions and methods for the preparation thereof for use in the methods of the present invention.Type: ApplicationFiled: October 18, 2011Publication date: December 19, 2013Applicant: ELCELYX THERAPEUTICS, INC.Inventors: Alain D. Baron, Martin R. Brown, Christopher R.G. Jones, Nigel R.A. Beeley
-
Publication number: 20130315868Abstract: Provided herein are compounds, compositions and methods for the treatment of liver disease and conditions, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.Type: ApplicationFiled: May 21, 2013Publication date: November 28, 2013Inventors: Benjamin Alexander MAYES, Adel M. MOUSSA, Alistair James STEWART
-
Patent number: 8569478Abstract: Compounds, methods and compositions for treating a host infected with human immunodeficiency virus and hepatitis B virus comprising administering an effective amount of a described 4?-C-substituted ?-D- and ?-L-nucleoside or a pharmaceutically acceptable salt or prodrug thereof, are provided.Type: GrantFiled: September 26, 2006Date of Patent: October 29, 2013Assignee: Gilead Pharmasset LLCInventors: Jinfa Du, Phillip Furman, Michael Joseph Sofia
-
Publication number: 20130281686Abstract: Provided are methods and intermediates for preparing diastereomerically pure phosphoramidate prodrugs of nucleosides of Formulas Ia and Ib: The compounds of Formula Ia and Ib are useful for the treatment Hepatitis C infections.Type: ApplicationFiled: July 19, 2011Publication date: October 24, 2013Applicant: GILEAD SCIENCES, INC.Inventors: Aesop Cho, Michael O'Neil Hanrahan Clarke, Scott Alan Wolckenhauer
-
Patent number: 8563530Abstract: Disclosed herein is a compound represented by formula 1 or its hydrate thereof in crystalline or crystal-like form.Type: GrantFiled: March 31, 2011Date of Patent: October 22, 2013Assignee: Gilead Pharmassel LLCInventors: Wonsuk Chang, Devan Naduthambi, Dhanapalan Nagarathnam, Ganapati Reddy Pamulapati, Bruce S. Ross, Michael Joseph Sofia, Hai-Ren Zhang
-
Patent number: 8551973Abstract: A purified compound having activity against hepatitis C virus is disclosed.Type: GrantFiled: December 23, 2009Date of Patent: October 8, 2013Assignee: Gilead Pharmasset LLCInventors: Donghui Bao, Wonsuk Chang, Dhanapalan Nagarathnam, Michael Joseph Sofia
-
Patent number: 8541569Abstract: The present invention provides building blocks and methods for synthesizing very pure RNA in a form that can efficiently be modified at the 3? end. Reverse RNA monomer phosphoramidites have been developed for RNA synthesis in 5??3? direction, leading to very clean oligo synthesis that allows for the introduction of various modifications at the 3?-end cleanly and efficiently. Higher coupling efficiency per step have been observed during automated oligo synthesis with the reverse RNA amidites disclosed herein, resulting in a greater ability to achieve higher purity and produce very long oligonucleotides. The use of the reverse RNA phosphoramidites in the synthetic process of this invention leads to oligonucleotides free of N+1 species.Type: GrantFiled: February 19, 2010Date of Patent: September 24, 2013Assignee: ChemGenes CorporationInventors: Suresh C. Srivastava, Naveen P. Srivastava
-
Publication number: 20130244966Abstract: The invention relates to fatty acid antiviral conjugates; compositions comprising an effective amount of a fatty acid antiviral conjugate; and methods for treating or preventing a viral infection comprising the administration of an effective amount of a fatty acid antiviral conjugate.Type: ApplicationFiled: December 12, 2012Publication date: September 19, 2013Applicant: CATABASIS PHARMACEUTICALS, INC.Inventors: Jill C. Milne, Michael R. Jirousek, Chi B. Vu, Allison Wensley, Amal Ting
-
Publication number: 20130237697Abstract: The present invention relates to building blocks and methods for the efficient synthesis of 5-hydroxymethylcytosine-containing nucleic acids such as DNA or RNA.Type: ApplicationFiled: November 11, 2011Publication date: September 12, 2013Applicant: LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHENInventors: Thomas Carell, Martin Munzel
-
Patent number: 8530640Abstract: The present disclosure provides bicyclic cyclohexitol nucleoside analogs of formula I and oligomeric compounds comprising these nucleoside analogs. These bicyclic nucleoside analogs are expected to be useful for enhancing properties of oligomeric compounds including for example nuclease resistance.Type: GrantFiled: February 6, 2009Date of Patent: September 10, 2013Assignee: Isis Pharmaceuticals, Inc.Inventors: Punit P. Seth, Michael T. Migawa, Eric E. Swayze, Quanlai Song, Mingming Han, Bruce S. Ross
-
Publication number: 20130225519Abstract: A nucleoside compound having activity against hepatitis C virus is disclosed.Type: ApplicationFiled: February 25, 2013Publication date: August 29, 2013Applicant: GILEAD PHARMASSET LLCInventor: GILEAD PHARMASSET LLC
-
Publication number: 20130210757Abstract: This application discloses phosphoramidate and phosphonoamidate prodrugs of alcohol-based therapeutic agents, such as nucleosides, nucleotides, acyclonucleosides, C-nucleosides, and C-nucleotides, and use of these prodrugs for treatment of diseases or disorders, including infectious diseases and cancers. This application also discloses a general method for enhancing bioavailability and/or liver-targeting property of alcohol drugs through converting the alcohol drugs to phosphoramidate or phosphonoamidate prodrugs, and methods of preparation of these prodrugs.Type: ApplicationFiled: March 15, 2013Publication date: August 15, 2013Applicant: NANJING MOLECULAR RESEARCH, INC.Inventor: NANJING MOLECULAR RESEARCH, INC.
-
Publication number: 20130203694Abstract: Rel proteins as a novel therapeutic agent for treating bacterial threats. More specifically, a novel class of compounds of Formula (I) as disclosed herein which possess anti-bacterial activity and which inhibit RelA, RelSeq or RelSpo synthetic activity or bacterial spore formation. Also, pharmaceutical compositions of such compounds and a method of combating bacteria, or treating bacterial infections, by administering to a subject in need thereof such compounds or pharmaceutical compositions.Type: ApplicationFiled: August 3, 2011Publication date: August 8, 2013Applicant: YISSUM RESEARCH DEVELOPMENT CO. OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.Inventors: Ezequiel Wexselblatt, Joshua Katzhendler, Gad Glaser, Sigal Ben Yehuda, Roee Vidavski, Hafiz Mawasi, Ilana Kaspy, Yaara Oppenheimer-Shaanan
-
Publication number: 20130203978Abstract: The invention provides a compound of formula (I), wherein R1-R6 and X have any of the values described, as well as pharmaceutical compositions comprising such compounds and therapeutic methods comprising the administration of such compounds.Type: ApplicationFiled: January 29, 2013Publication date: August 8, 2013Applicant: Regents of the University of MinnesotaInventor: Regents of the University of Minnesota
-
Patent number: 8501931Abstract: The present invention is directed to convertible nucleosides and polymer supported convertible nucleosides for use in SNAr displacement reactions. The convertible nucleosides can be used to synthesize numerous substituted purine and pyrimidine derivatives.Type: GrantFiled: October 12, 2007Date of Patent: August 6, 2013Assignee: Research Foundation of the City University of New YorkInventors: Mahesh K. Lakshman, Suyeal Bae
-
Publication number: 20130184160Abstract: The present disclosure encompasses oligonucleotide aptamers selectively binding a target glycosylated polypeptide or protein, and having biased affinity for the glycan through a boronic acid linked to a nucleosidic base of a nucleotide(s). The disclosure further encompasses methods for isolating an aptamer(s) selectively binding a target glycosylated polypeptide, where, from a population of randomized oligonucleotides that have at least one nucleotide having a boronic acid label linked to a base, is selected a first subpopulation of aptamers binding to the target glycosylated polypeptide or protein. This subpopulation is then amplified without using boronic acid-modified TTP, and amplification products not binding to a target glycosylated polypeptide or protein are selected. The second subpopulation of aptamers is then amplified using boronic acid-modified TTP to provide a population of boronic acid-modified aptamers capable of selectively binding to a glycosylation site of a target polypeptide or protein.Type: ApplicationFiled: July 17, 2008Publication date: July 18, 2013Inventors: Binghe Wang, Minyong Li, Zhen Huang, Na Lin
-
Publication number: 20130164261Abstract: Disclosed herein are phosphorothioate nucleotide analogs, methods of synthesizing phosphorothioate nucleotide analogs and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with the phosphorothioate nucleotide analogs.Type: ApplicationFiled: December 20, 2012Publication date: June 27, 2013Applicant: ALIOS BIOPHARMA, INC.Inventor: ALIOS BIOPHARMA, INC.
-
Publication number: 20130165399Abstract: The present invention has an object to provide an effective and safe therapeutic agent for inflammatory diseases such as sepsis, hepatitis, and inflammatory bowel disease, and solves the above object by providing a therapeutic agent for inflammatory diseases containing adenosine N1-oxide or a derivative thereof as an effective ingredient.Type: ApplicationFiled: June 16, 2011Publication date: June 27, 2013Applicant: HAYASHIBARA CO., LTD.Inventors: Keizo Kohno, Emiko Ohashi, Hajime Kusano, Shigeharu Fukuda, Tatsuya Ishihara
-
Publication number: 20130130378Abstract: This invention relates to acyclic and abasic nucleosides and oligonucleotides prepared therefrom. For instance, oligonucleotides can be prepared having one or more of the following formulas (I-III):, or isomers thereof.Type: ApplicationFiled: April 22, 2011Publication date: May 23, 2013Applicant: ALNYLAM PHARMACEUTICALS, INC.Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Jeremy Lackey, Narayanannair K. Jayaprakash
-
Publication number: 20130129651Abstract: The present invention has objects to provide an agent for enhancing the effect of skin-whitening ingredients which enhances the skin-whitening action of skin-whitening ingredients and has an improved safeness, and to provide a skin-whitening agent, which contains the above agent and a skin-whitening ingredient(s) and has an improved and enhanced skin-whitening action. The present invention solves the above objects by providing an agent for enhancing the effect of skin-whitening ingredients, which contains one or more members selected from the group consisting of guanine and derivatives thereof as an effective ingredient(s); and a skin-whitening agent which contains the above agent along with a skin-whitening ingredient(s) particularly, members derivatives thereof and/or equol including derivatives thereof.Type: ApplicationFiled: July 28, 2011Publication date: May 23, 2013Applicant: HAYASHIBARA CO., LTD.Inventors: Masaki Miyake, Osamu Sano, Kanso Iwaki, Takanori Okura, Shigeharu Fukuda
-
Patent number: 8440812Abstract: The invention relates to analogous compounds of 6-thioguanosine triphosphate of general formula (I). A compound of the general formula (I); wherein the dashed bond in the sugar moiety can be either single or double and wherein R1, R2, R3, R4 or R5, equal or different between each other, have general formula -(Int)m-Ter, wherein m is between 0 and 12 and Int and Ter are Internal and Terminal building blocks, wherein Int is selected from the group consisting of formula (II); and Ter is selected from the group consisting of formula (III).Type: GrantFiled: December 20, 2011Date of Patent: May 14, 2013Assignee: Nogra Pharma LimitedInventors: Giancarlo Naccari, Sergio Baroni
-
Publication number: 20130102652Abstract: Disclosed are compositions and methods related to modified nucleobases. Also disclosed are compositions and methods related to modified interfering RNAs. Also disclosed are compositions and methods related to modified adenonsine for controlling off-target effects in RNA interference.Type: ApplicationFiled: March 23, 2011Publication date: April 25, 2013Applicant: UNIVERSITY OF UTAH RESEARCH FOUNDATIONInventors: Cynthia J. Burrows, Uday Ghanty
-
Publication number: 20130090301Abstract: An object of the present invention is to provide an agent for suppressing the formation of skin cells induced by exposure to light such as ultraviolet light. The object is achieved by using a purine nucleic acid for suppressing the formation of abnormal skin cells caused by exposure to light.Type: ApplicationFiled: June 24, 2011Publication date: April 11, 2013Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Mitsuaki Kawamura, Shigeo Shinohara, Fumiki Harano, Akihiro Aoki, Eri Ueno
-
Patent number: 8399428Abstract: The invention provides a compound of formula (I), wherein R1-R6 and X have any of the values described, as well as pharmaceutical compositions comprising such compounds and therapeutic methods comprising the administration of such compounds.Type: GrantFiled: December 8, 2005Date of Patent: March 19, 2013Assignee: Regents of the University of MinnesotaInventor: Carston R. Wagner
-
Publication number: 20130064794Abstract: Provided herein are compounds, compositions and methods for the treatment of liver disorders, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.Type: ApplicationFiled: September 11, 2012Publication date: March 14, 2013Applicant: IDENIX PHARMACEUTICALS, INC.Inventors: Dominique Surleraux, Cyril B. Dousson, Gilles Gosselin, David Dukhan, Claire Pierra, Jerome Peyronnet
-
Publication number: 20130059343Abstract: The present invention provides compounds and methods for attaching fluorescent labels to biological molecules such as nucleotides. The compounds and methods are useful for biological assays including DNA modification reactions.Type: ApplicationFiled: August 8, 2012Publication date: March 7, 2013Applicant: LI-COR, INC.Inventor: Lael Cheung
-
Publication number: 20130053338Abstract: Pharmaceutical compositions containing P2X purinergic agonists, e.g. P2X3 agonists, for increasing insulin secretion in a subject, methods of use, and methods of screening for related compounds and agents.Type: ApplicationFiled: March 21, 2011Publication date: February 28, 2013Inventors: Per-Olof Berggren, Alejandro Caicedo, Caroline M. Jacques-Silva
-
Publication number: 20130052690Abstract: A primer or primer pair comprising a 3?-photolabile group, and a method of amplifying nucleic acids with controlled polymerization using the primer or primer pair, as well as related compositions, kits, and device for amplifying nucleic acids.Type: ApplicationFiled: August 13, 2012Publication date: February 28, 2013Applicant: SAMSUNG ELECTRONICS CO., LTD.Inventors: Sung-min CHI, Sung-ouk JUNG, Sun-ok JUNG, Joon-ho KIM
-
Publication number: 20130045475Abstract: This disclosure provides novel reversibly terminated ribonucleotides which can be used as a reagent for DNA sequencing reactions. Methods of sequencing nucleic acids using the disclosed nucleotides are also provided.Type: ApplicationFiled: October 23, 2012Publication date: February 21, 2013Applicant: ALERE SAN DIEGO, INC.Inventor: Alere San Diego, Inc.
-
Publication number: 20130040908Abstract: Substitution derivatives of N6-benzyladenosine-5?-monophosphate of the general formula I, wherein (R)n represents 1 to 4 substituents (n is in the range 1-4), which can be the same or different, and R is selected from the group comprising C1 to C8 alkyl, C1 to C8 alkoxy, amino, halogen, hydroxy, mercapto and nitro groups, and the pharmaceutically acceptable salts thereof. A Method for their preparation, their use as medicaments and in other applications, and a therapeutic composition containing these derivatives is also disclosed.Type: ApplicationFiled: April 28, 2011Publication date: February 14, 2013Applicants: BIOAPEX, S.R.O., UNIVERZITA PALACKEHO V OLOMOUCIInventors: Marek Zatloukal, Karel Dolezal, Jiri Voller, Lukas Spichal, Miroslav Strnad
-
Publication number: 20130041144Abstract: Provided herein are novel 5?-(S)—CH3 substituted bicyclic nucleosides, oligomeric compounds prepared therefrom and methods of using the oligomeric compounds. More particularly, the furanose ring of each of the novel 5?-(S)—CH3 substituted bicyclic nucleosides includes a 2? to 4? bridging group. The 5?-(S)—CH3 substituted bicyclic nucleosides are expected to be useful for enhancing one or more properties of the oligomeric compounds they are incorporated into such as for example increasing the binding affinity. In certain embodiments, the oligomeric compounds provided herein hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.Type: ApplicationFiled: March 10, 2011Publication date: February 14, 2013Applicant: Isis Pharmaceuticals, Inc.Inventors: Michael T. Migawa, Thazha P. Prakash, Charles Allerson, Balkrishen Bhat, Punit P. Seth, Eric E. Swayze
-
Patent number: 8361988Abstract: The present invention comprises compounds useful as antiviral or antitumor agents. The compounds comprise nucleotide analogues that comprise tetrahydrofuranyl or tetrahydrothienyl moeities with quaternary centers at the 3? position. The nucleotide analogues can be used to inhibit cancer or viruses. Accordingly, the compounds of the present invention are useful for treating, preventing, and/or inhibiting diseases or conditions associated with cancers and viruses. Thus, the present invention also comprising pharmaceutical formulations comprising the compounds and methods of using the compounds and formulations to inhibit viruses or tumors and treat, prevent, or inhibit the foregoing diseases.Type: GrantFiled: January 17, 2008Date of Patent: January 29, 2013Assignee: Institut de Recherches Cliniques de MontrealInventor: Yvan Guindon
-
Publication number: 20130017973Abstract: To provide a functional molecule including a modified nucleotide unit having a substituent introduced to a base thereof, wherein the substituent is removably introduced to the base; a functional molecule synthesizing amidite that has a substituent removably introduced to its base and that is used for the manufacture of the functional molecule; and a target substance analysis method including: preparing a random pool of functional molecules using a functional molecule synthesizing amidite; screening a functional molecule having affinity for a target substance from the random pool; amplifying the functional molecules having affinity for the target substance, wherein the method further comprises, prior to the amplification step, removing a substituent from the functional molecule having affinity for the target substance.Type: ApplicationFiled: August 30, 2012Publication date: January 17, 2013Applicant: FUJITSU LIMITEDInventors: Tsuyoshi Fujihara, Shozo Fujita
-
Patent number: RE44779Abstract: An oligo- or polynucleotide analogue having one or more structures of the general formula where B is a pyrimidine or purine nucleic acid base, or an analogue thereof, is disclosed. The use of this analogue provides an oligonucleotide analogue antisense molecule, which is minimally hydrolyzable with an enzyme in vivo, has a high sense strand binding ability, and is easily synthesized.Type: GrantFiled: June 26, 2012Date of Patent: February 25, 2014Assignees: Santaris Pharma A/S, Exiqon A/SInventors: Takeshi Imanishi, Satoshi Obika